<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967925</url>
  </required_header>
  <id_info>
    <org_study_id>206852</org_study_id>
    <nct_id>NCT03967925</nct_id>
  </id_info>
  <brief_title>Rituximab and Belimumab Combination Therapy in PR3 Vasculitis</brief_title>
  <acronym>COMBIVAS</acronym>
  <official_title>A Randomised, Double Blind, Controlled Mechanistic Study of Rituximab and Belimumab Combination Therapy in PR3 ANCA-associated Vasculitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rachel Jones</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newcastle University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mechanistic study to assess whether dual B-cell immunotherapy by co-administration of
      rituximab and belimumab will result in improvements in biological endpoints, functional
      outcomes and clinical status compared to rituximab with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to PR3 ANCA negativity</measure>
    <time_frame>Analysed at 24 months</time_frame>
    <description>ELISA analysis at different time points to determine when PR3 ANCA can no longer be detected</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with PR3 ANCA negativity</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by ELISA at various time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of certain cell subsets</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by flow cytometry at various time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical remission</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by BVAS/WG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>2 years</time_frame>
    <description>Hospitalisation or serious events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>ANCA Associated Vasculitis</condition>
  <condition>Granulomatosis With Polyangiitis</condition>
  <arm_group>
    <arm_group_label>Belimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weekly 200mg SC injections of belimumab for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belimumab placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly SC injections of belimumab placebo for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belimumab</intervention_name>
    <description>Sub-cutaneous injection</description>
    <arm_group_label>Belimumab</arm_group_label>
    <other_name>Benlysta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>IV infusion 1g x 2</description>
    <arm_group_label>Belimumab</arm_group_label>
    <arm_group_label>Belimumab placebo</arm_group_label>
    <other_name>Truxima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>20mg prednisolone tapering dose</description>
    <arm_group_label>Belimumab</arm_group_label>
    <arm_group_label>Belimumab placebo</arm_group_label>
    <other_name>prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must be 18 of age

          -  Have a diagnosis of AAV (granulomatosis with polyangiitis or microscopic polyangiitis)

          -  Have PR3 ANCA positivity by ELISA at screening

          -  Have active disease defined by one major or three minor disease activity items on
             BVAS/WG

          -  Be capable of giving signed informed consent

        Exclusion Criteria:

          -  MPO ANCA or anti-GBM antibody positivity by ELISA at screening

          -  Presence of pulmonary haemorrhage with hypoxia at screening

          -  Estimated glomerular filtration rate (eGFR) &lt;30 ml/min/1.73m2 at screening

          -  Have an acute serious or chronic infection at screening

          -  Have received any B cell targeted therapy within 364 days of Day 1

          -  Have received any steroid injection (e.g., intramuscular [IM], intraarticular, or IV)
             within 60 days of Day 1 (unless given during or 14 days before screening period)

          -  Have received &gt;1.5mg methylprednisolone (IV) between 14 days prior to screening and
             Day 1 (including Day 1).

          -  Have received oral prednisolone &gt;10mg/day (or equivalent) on average over the 30 days
             prior to screening

          -  Have undetectable peripheral blood B cells at screening

          -  Have IgG &lt;400mg/dl at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Mynard</last_name>
      <phone>01223 349350</phone>
      <email>kim.mynard@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rachel Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Freemann Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 18, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Rachel Jones</investigator_full_name>
    <investigator_title>Consultant Nephrologist</investigator_title>
  </responsible_party>
  <keyword>proteinase 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Belimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

